. . . . "Ovlivn\u011Bn\u00ED farmakokinetiky jin\u00FDch l\u00E9\u010Div\u00FDch p\u0159\u00EDpravk\u016F escitalopramem\nEscitalopram je inhibitor enzymov\u00E9ho syst\u00E9mu CYP2D6. Doporu\u010Duje se ur\u010Dit\u00E1 opatrnost p\u0159i sou\u010Dasn\u00E9m u\u017Eit\u00ED escitalopramu a l\u00E9\u010Div\u00FDch l\u00E1tek, kter\u00E9 jsou metabolizovan\u00E9 hlavn\u011B t\u00EDmto enzymov\u00FDm syst\u00E9mem, a kter\u00E9 maj\u00ED\u00A0\u00FAzk\u00FD terapeutick\u00FD index, nap\u0159. flekainid, propafenon a metoprolol (pokud je pou\u017Eit p\u0159i srde\u010Dn\u00EDm selh\u00E1n\u00ED) nebo n\u011Bkter\u00FDch l\u00E1tek ovliv\u0148uj\u00EDc\u00EDch CNS, metabolizovan\u00FDch p\u0159ev\u00E1\u017En\u011B syst\u00E9mem CYP2D6 (antidepresiva: desipramin, klomipramin a nortriptylin; antipsychotika: risperidon, thioridazin a haloperidol)."@cs . . . . . . . . "19849"^^ . "20422"^^ . "1"^^ . . . .